uniQure N.V. (LON:0EE0)
United Kingdom · Delayed Price · Currency is GBP · Price in USD | Market Cap | 1.17B -9.8% |
| Revenue (ttm) | 15.19M +28.0% |
| Net Income | -175.43M |
| EPS | -2.68 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 207 |
| Open | 22.79 |
| Previous Close | 22.47 |
| Day's Range | 22.25 - 23.50 |
| 52-Week Range | 7.50 - 53.00 |
| Beta | 1.06 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About uniQure
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase ... [Read more]
Financial Performance
In 2025, uniQure's revenue was $16.10 million, a decrease of -40.64% compared to the previous year's $27.12 million. Losses were -$198.97 million, -16.94% less than in 2024.
Financial numbers in USD Financial StatementsNews
uniQure Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
FDA review will use the original Enroll-HD A-cut BLA dataset, while management points to durable TFC trends through 48 months. The 200-patient confirmatory study is advancing, with enrollment and treatment-center readiness prioritized.
uniQure Earnings Call Transcript: Q3 2026
AMT-130 received FDA Priority Review with a May 1, 2027 decision date, while confirmatory-trial and launch preparations advance. Q3 revenue was $5.2M and cash and investments totaled $768.4M, providing runway into 2030.
uniQure Earnings release: Q3 2026
uniQure released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
uniQure Quarterly report: Q3 2026
uniQure has published its Q3 2026 quarterly earnings report on November 4, 2026.
uniQure reports Q3 EPS (88c), consensus (82c)
Reports Q3 revenue $5.2M, consensus $5.43M. “Over the last few months, we have made significant progress in our mission to potentially deliver the first disease-modifying therapy to the patients and…
uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update
~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington's disease; PDUFA target action date of May 1, 2027 ~
uniQure announces FDA acceptance, priority review for ifezuntirgene inilparvovec
uniQure (QURE) announced the FDA has accepted for review the biologics license application, or BLA, for ifezuntirgene inilparvovec, an investigational gene therapy for the treatment of Huntington’s di...
uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington's Disease
~ FDA sets PDUFA target action date of May 1, 2027 ~ ~ If approved, ifezuntirgene inilparvovec will be the world's first disease-modifying treatment for Huntington's disease ~ LEXINGTON, Mass. and AMS...
uniQure to Announce Third Quarter 2026 Financial Results
~ uniQure to host earnings call on Wednesday, November 4, 2026 at 8:30 a.m. ET ~ ~ uniQure to host earnings call on Wednesday, November 4, 2026 at 8:30 a.m. ET ~
uniQure assumed with a Buy at UBS
UBS assumed coverage of uniQure (QURE) with a Buy rating with a price target of $48, up from $27. The company’s AMT-130 may be the first disease-modifying therapy approved for…
uniQure downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded uniQure (QURE) to Equal Weight from Overweight with a price target of $28, down from $60. The firm sees increased uncertainty around for AMT-130 in Huntington’s disease following…
uniQure price target lowered to $48 from $65 at RBC Capital
RBC Capital analyst Luca Issi lowered the firm’s price target on uniQure (QURE) to $48 from $65 and keeps an Outperform rating on the shares. The firm is updating its…
uniQure price target lowered to $31 from $46 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on uniQure (QURE) to $31 from $46 and keeps a Neutral rating on the shares. The firm is updating its model following the…
uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)
uniQure's four-year AMT-130 Huntington's disease benefit came in smaller than its three-year result, and QURE shares plummeted. SueWallSt notifies investors of a pending investigation into potential s...
uniQure weakness creates attractive opportunity, says Wells Fargo
Wells Fargo reiterated an Overweight rating and $75 price target on uniQure (QURE). New four-year data on UHDRS, a secondary endpoint that appears confounded by the dynamics in the external…
RBC says uniQure’s four-year HD data mixed, stock reaction ‘overdone’
RBC Capital analyst Luca Issi notes the uniQure (QURE) updated three-year data and reported first look at the four-year data for Huntington’s disease. The firm believes the data is clearly…
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $QURE--QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law.
uniQure ‘mixed’ four-year data complicates durability case, says H.C. Wainwright
After uniQure (QURE) announced additional data from the ongoing Phase I/II studies of ifezuntirgene inilparvovec for the treatment of Huntington’s disease, including outcomes for the 36-month and 48-m...
UniQure Insists Huntington's Drug Is Still on Track as Stock Plunges 48%
UniQure says it still sees a path to regulatory approval for the drug candidate, AMT-130, even as the experimental gene therapy for Huntington's disease falls hort in a recent study.
uniQure Transcript: Study update
At 48 months, high-dose AMT-130 showed 61% TFC slowing and 44% cUHDRS slowing versus the updated control; the cUHDRS result was not statistically significant. The expanded 36-month analysis showed 80% cUHDRS and 67% TFC slowing.
uniQure Press release: Study update
uniQure issued a press release on September 29, 2026, disclosing material business information to investors.
uniQure Slides: Study update
uniQure has posted slides in relation to its latest quarterly earnings report, which was published on September 29, 2026.
Why is uniQure Stock (QURE) Down Nearly 60% Today?
Shares in gene therapy company uniQure ($QURE) plunged in pre-market trading today after it revealed that the effectiveness of its Huntington’s disease-fighting drug fades in the fourth year of treatm...